| 62.93 4.4 (7.52%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 95.74 | 1-year : | 114.35 |
| Resists | First : | 81.97 | Second : | 97.91 |
| Pivot price | 70.11 |
|||
| Supports | First : | 56.2 | Second : | 46.75 |
| MAs | MA(5) : | 64.15 |
MA(20) : | 72.05 |
| MA(100) : | 57.55  |
MA(250) : | 36.88 |
|
| MACD | MACD : | -1.2 |
Signal : | 1 |
| %K %D | K(14,3) : | 17 |
D(3) : | 18.7 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 97.91 | Low : | 9.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KRRO ] has closed above bottom band by 18.8%. Bollinger Bands are 10.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 63.33 - 63.71 | 63.71 - 64.08 |
| Low: | 57.37 - 57.79 | 57.79 - 58.2 |
| Close: | 62.24 - 62.9 | 62.9 - 63.54 |
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Wed, 24 Apr 2024
Korro Bio (NASDAQ:KRRO) Shares Down 5.7% - MarketBeat
Tue, 23 Apr 2024
Korro Bio, Inc. (NASDAQ:KRRO) Major Shareholder Buys $999,992.00 in Stock - MarketBeat
Tue, 23 Apr 2024
Atlas Venture opportunity fund II L.P. acquires $1m in Korro Bio shares - Investing.com South Africa
Fri, 19 Apr 2024
Korro Bio (NASDAQ:KRRO) Shares Gap Down to $66.78 - MarketBeat
Wed, 03 Apr 2024
Korro Bio (NASDAQ:KRRO): What to Make of the Surge in Stock Value - TipRanks.com - TipRanks
Sat, 30 Mar 2024
We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business Growth - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 81.8 (%) |
| Shares Short | 108 (K) |
| Shares Short P.Month | 124 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.8 % |
| Return on Equity (ttm) | -69.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -67 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|